Molbio Diagnostics Q1 FY27: 25% Growth Guidance, ₹200 Crore Capex and Strong Truenat Expansion Plans
Molbio Diagnostics Limited (MOLBIO) has outlined an ambitious growth strategy following its Q1 FY27 earnings call, with management targeting around 25% revenue growth in FY27 and an EBITDA margin of 24%–25%.
The company is looking to expand its Truenat point-of-care molecular diagnostics platform globally while increasing recurring test-kit sales. At the same time, investments in automation, R&D, HPV testing, digital pathology and international markets are expected to create additional growth opportunities.
Q1 FY27 Results
Molbio Diagnostics reported consolidated revenue from operations of ₹408 crore in Q1 FY27. The company sold 164 Truenat devices and 62.4 lakh test kits during the quarter.
Export revenue stood at approximately ₹67 crore, contributing around 16% of total revenue. EBITDA came in at ₹104 crore, representing an EBITDA margin of about 25%, while profit after tax stood at ₹52.7 crore, equivalent to roughly 13% of revenue.
The company also reported an improvement in inventory efficiency, with trailing 12-month inventory days falling to 230 days in June from 280 days in March. Receivable days were broadly stable at 87 days compared with 86 days in March.
FY27 Revenue Growth Guidance
Management expects Molbio’s top line to grow by approximately 25% in FY27, while targeting an EBITDA margin of around 24%–25%.
The company cautioned that its quarterly performance should not be viewed on a simple sequential or year-on-year basis because its business has significant exposure to public-health programmes, tenders and government procurement cycles.
Management therefore encouraged investors to evaluate the business primarily on an annual basis.
₹200 Crore IPO-Funded Capex Plan
Molbio has raised ₹200 crore through its IPO, with a substantial portion earmarked for automation and R&D infrastructure.
Around ₹72 crore will be invested in automation, while approximately ₹105 crore will be used to establish an integrated R&D centre in Bengaluru.
The automation investment is expected to improve manufacturing efficiency and increase the company’s ability to scale revenue without requiring significant new manufacturing capacity.
Management said test-kit capacity utilisation is currently around 58%, while device capacity utilisation is approximately 42%.
As a result, the company believes existing capacity is sufficient to potentially support 2x revenue from FY26 levels with limited additional manufacturing capex.
R&D Remains a Key Growth Engine
Molbio said it generally invests around 5%–6% of revenue in R&D and expects to maintain this level.
The company has significantly increased its R&D investment, with annual spending rising from around ₹59.8 crore in FY24 to more than ₹216 crore over the last three years.
Importantly, management said the bulk of future R&D investment will focus on new diagnostic platforms, rather than only expanding the existing Truenat test menu.
The company is working on both infectious-disease and non-communicable-disease platforms, with the aim of bringing more diagnostic parameters closer to the point of care.
Truenat Expansion: 12,500 Machines Across 90+ Countries
Molbio’s Truenat platform has reached approximately 12,500 installed machines across more than 90 countries.
The platform currently supports around 30 diseases through 43 assays, with the company planning to add another 22 diseases through 34 additional assays.
The company believes this expansion can increase utilisation of its existing installed base and drive recurring revenue through consumable sales.
Around 75% of Molbio’s revenue currently comes from test kits, highlighting the importance of the recurring consumables model.
TB Business Has Further Growth Runway
Tuberculosis remains the largest component of Molbio’s domestic business, but management believes significant room for expansion remains.
According to management, India has approximately 25,000–30,000 TB diagnostic centres, while Truenat has so far been deployed at around 8,000–9,000 centres.
The remaining centres primarily continue to use traditional microscopy rather than another molecular platform.
Management expects the continued transition from microscopy to molecular diagnostics to create opportunities for additional Truenat installations and recurring test-kit sales.
The company also recently secured a two-year rate contract for its TB business with the Government of India, providing near-term business visibility.
HPV Testing Could Become a New Growth Driver
Molbio’s Truenat HPV test has completed extensive validation in India.
Management said the validation process, led by AIIMS and involving international agencies, found Truenat to meet the required international criteria. A health technology assessment also found the test to be cost-effective at the offered price.
The company expects the test to potentially be introduced into the national programme as the implementation process progresses.
Molbio is also working toward WHO prequalification, which could provide access to international markets.
However, management has not yet provided specific HPV volume guidance and expects greater visibility over potential volumes in the coming quarters.
Export Business Expected to Become Important Growth Driver
Molbio’s export business is still relatively young, with international activities having started around 2023.
The company currently has distributors and registrations across more than 90 countries and is expanding its presence in both emerging and developed markets.
Management said the earlier volatility in exports was partly due to different countries starting at different times, but the business is now moving toward greater stabilisation.
Europe is emerging as a new opportunity following the company’s EU IVDR certification for its Truenat CT/NG test.
The company is also evaluating the U.S. market and expects international business to become an increasingly important contributor to future growth.
OptraScan: U.S. Market Opportunity
Molbio’s digital pathology subsidiary OptraScan received U.S. FDA clearance in July 2026 for its digital pathology solution, including the machine, software, and AI-enabled workflow.
Management sees significant potential in the U.S., which it estimates accounts for around 60% of the global pathology market.
Discussions and demonstrations with large laboratory and hospital networks in the U.S. are already underway.
However, management does not expect OptraScan to become profitable in FY27. Meaningful financial contribution is expected from FY28–FY29 onwards.
The company also stated that OptraScan is currently sufficiently funded and does not expect to require additional capital for the next two to three years.
Prognosys Adds Another Growth Opportunity
Molbio owns a 70% stake in Prognosys, which operates in digital imaging.
The business generated around ₹154 crore of revenue and approximately ₹12 crore of PAT in FY26, according to management.
The company has also received regulatory approvals for its digital imaging solutions and is developing opportunities around its ultra-portable handheld X-ray technology.
Management sees potential applications in tuberculosis screening as well as the veterinary and companion-animal markets, particularly in developed countries.
Acquisitions and Partnerships Remain Part of Strategy
Management said acquisitions will remain an important component of Molbio’s growth strategy.
The company has already expanded beyond Truenat through its investments in Prognosys and OptraScan, increasing its exposure to digital X-ray and digital pathology.
Molbio is also pursuing partnerships with MedTech companies. Its Edge programme identifies promising healthcare and MedTech startups that could potentially lead to go-to-market partnerships, licensing arrangements or strategic investments.
Management Commentary on Business Model
Management highlighted the recurring nature of the Truenat business.
The device represents a one-time hardware sale, while the proprietary cartridges and chips are consumed with every test.
Because Truenat operates as a closed system, third-party consumables cannot be used with the company’s devices.
Management said machines installed as early as 2017–18 are still operating, with no replacement cycle having emerged so far.
This could allow older as well as newer installations to continue generating recurring consumables revenue.
Gross Margin and Realisation
Molbio said its overall business typically operates at around 60%–63% gross margin across devices and test kits.
Quarterly changes in realisation can be influenced by the product mix between single-bay, two-bay and four-bay devices, as well as geographic mix and currency movements.
The company does not operate primarily on an MRP-based model because pricing is generally determined through contracts with various agencies and can depend on volumes.
Important Investor Point: New Platforms Could Expand TAM
One of the more significant comments from the earnings call was regarding Molbio’s future non-communicable disease platforms.
Management believes infectious diseases represent only a small part of the overall diagnostic investigation market.
The company is therefore developing new point-of-care platforms that follow the Truenat philosophy of being portable, battery-operated, easy to use, connected and requiring minimal training.
Management indicated that the total addressable opportunity for these future tests could be at least 10 times larger than the current molecular-testing opportunity, although specific platforms and commercial timelines have not yet been disclosed.
Investor Takeaway
Molbio Diagnostics enters FY27 with a combination of 25% revenue-growth guidance, a 24%–25% EBITDA margin target, substantial unused manufacturing capacity and a growing recurring test-kit business.
The company’s ₹200 crore IPO-funded investment, including ₹72 crore for automation and around ₹105 crore for the Bengaluru R&D centre, is aimed at improving efficiency and strengthening its innovation pipeline.
In the near term, TB deployment, the two-year government rate contract and test-kit consumption remain important business drivers. Over the medium to long term, HPV testing, exports, Europe, OptraScan, digital X-ray and new point-of-care platforms could broaden Molbio’s growth base.
The key risks for investors include the timing of government programmes and tenders, the non-linear nature of quarterly revenue, the pace of international expansion and the time required for new platforms such as OptraScan to reach meaningful profitability.
Key Numbers to Track
- Q1 FY27 Revenue: ₹408 crore
- Q1 EBITDA: ₹104 crore
- EBITDA Margin: 25%
- Q1 PAT: ₹52.7 crore
- Test Kits Sold: 62.4 lakh
- Devices Sold: 164
- FY27 Revenue Growth Guidance: ~25%
- FY27 EBITDA Margin Guidance: 24%–25%
- IPO Proceeds: ₹200 crore
- Automation Capex: ₹72 crore
- R&D Centre Capex: ~₹105 crore
- Truenat Installed Base: ~12,500 machines
- Countries: 90+
- Current Test Menu: 30 diseases / 43 assays
- Additional Pipeline: 22 diseases / 34 assays
- TB Centres Covered: ~8,000–9,000
- Estimated TB Diagnostic Centres in India: ~25,000–30,000
Source: Molbio Diagnostics Q1 FY27 Earnings Conference Call transcript dated September 8, 2026. The company has stated that the transcript may contain transcription errors.
Disclaimer
This article is based on the company’s earnings-call transcript and management commentary. Forward-looking statements, guidance, and business expectations are subject to risks and uncertainties. Investors should independently evaluate the company’s financials, valuations, and disclosures before making investment decisions. This article is for informational purposes only and is not investment advice.